Engineered E. coli Nissle 1917 for Uric Acid Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gout and hyperuricemia, such as low-purine diets and drugs like allopurinol, have limited effectiveness, and there is a lack of recombinant probiotics capable of efficiently degrading uric acid in the human body.
Innovation Solution
Engineering the probiotic Escherichia coli Nissle 1917 by integrating exogenous genes like urate oxidase, urate transporter, hemoglobin, and catalase into its genome to create a strain that can efficiently degrade uric acid in both oxygen-rich and hypoxic environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments like low-purine diet and allopurinol are used, then blood uric acid concentration can be controlled, but treatment effectiveness is limited and side effects occur
Solution Approach 1:
The patent introduces engineered probiotics as a biological intermediary that mediates uric acid degradation in the gut. The probiotics express urate oxidase enzyme to convert uric acid into allantoin, providing an alternative degradation pathway that bypasses the limitations of conventional treatments and reduces reliance on medications with side effects
Solution Approach 2:
The patent replaces the mechanical/pharmacological approach of allopurinol (which inhibits xanthine dehydrogenase) with a biological enzymatic system. The engineered probiotics deliver functional urate oxidase directly to the gut, substituting drug-based inhibition with enzyme-based degradation, thereby improving effectiveness and reducing harmful effects
2Reliability
If probiotics are orally administered to reduce blood uric acid, then some reduction is achieved, but the degree of reduction is limited
Solution Approach 1:
The patent modifies key parameters of the probiotic system by introducing exogenous genes (urate oxidase, urate transporter, hemoglobin, catalase) into the probiotic genome. These genetic modifications enable the probiotics to produce urate oxidase enzyme and acquire enhanced capabilities for uric acid uptake and metabolism, dramatically improving degradation efficiency from limited to significant reduction
Solution Approach 2:
The patent creates composite functional capabilities within the probiotic by combining multiple gene products: urate oxidase for degradation, urate transporter for uptake, hemoglobin for oxygen supply, and catalase for protective enzyme activity. This composite system enables high-efficiency uric acid degradation that overcomes the limitations of unmodified probiotics
3Reliability
If engineered probiotics are constructed to degrade uric acid, then therapeutic effect is improved, but the complexity of construction increases
Solution Approach 1:
The patent divides the uric acid degradation system into modular genetic components that can be independently constructed and assembled. Each gene (urate oxidase, urate transporter, hemoglobin, catalase) functions as a separate module that can be cloned, optimized, and integrated into the probiotic genome using standard molecular biology techniques, making the complex construction process manageable and reproducible
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered probiotic demonstrates strong uric acid degradation ability and improved therapeutic effect, providing a promising treatment for gout and hyperuricemia by effectively reducing uric acid levels in the body.
Implementation Method 1
The engineered probiotic can also rapidly degrade UA in the intestine and blood of mice... one or more exogenous genes selected from a urate oxidase gene, a urate transporter gene, a hemoglobin gene, and a catalase gene are integrated into its genome
Implementation Method 2
a class of transport proteins on the intestine: ABCG2, can transport UA to the intestine... one or more exogenous genes selected from a urate oxidase gene, a urate transporter gene
Implementation Method 3
a hemoglobin gene... The human intestine is not a completely anaerobic environment as traditionally understood, but the oxygen concentration shows a gradient distribution
Implementation Method 4
a catalase gene... Integrated into its genome
Data Source
AI summary
Provided are an engineering probiotic for degrading uric acid, and a construction method therefor and the use thereof, which belongs to the field of biotechnology. The probiotic Escherichia coli Nissle 1917 is used as an original starting strain, and an exogenous gene is introduced into a genome thereof by means of genetic engineering technology for modification, such that uric acid can be efficiently and rapidly degraded; and it is proved by tests that the rapid degradation of uric acid can be achieved in the intestinal tract and blood of mice. Compared with current lactic acid bacteria for degrading uric acid in the market, the constructed engineering probiotic has a stronger degradation ability and a better treatment effect, and therefore has a good practical application value.